Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
The present invention relates to the use of compositions for monitoring, diagnosis, detecting, and treating a cancer condition in a subject. The use of composition comprises methods of monitoring, diagnosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.
1. A method for treating or preventing cancer in a subject, comprising administering to the subject a pharmaceutical composition comprising an effective amount of at least one agent that inhibits at least one of SATB2 expression, SATB2 transcriptional activity, EN2 expression, or EN2 transcriptional activity, wherein
SATB2 and EN2 are expressed in the cancer,
the cancer is selected from the group consisting of human breast cancer, prostate cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, cancer stem cells, mesothelioma, brain cancer, ovarian cancer, head and neck cancer, sarcoma, kidney cancer, melanoma, multiple myeloma, leukemia, and lymphoma, and
the at least one agent is a small organic molecule which inhibits SATB2 expression or SATB2 transcriptional activity, and is represented by a compound having the chemical structure of:
or the at least one agent is a small organic molecule which inhibits EN2 expression, or EN2 transcriptional activity, and is represented by a compound having the chemical structure of:
2. The method of claim 1 , wherein the at least one agent is modified by at least one functional group selected from hydroxyl, methyl, carbonyl, carboxyl, amino, nitro, ether, phosphate, fluorine, sulhydryl, fluromethyl, and ester group.
3. The composition of claim 1 , wherein the at least one agent comprises a targeting moiety capable of binding to the surface of a cancer cell, wherein said targeting moiety is selected from the group consisting of aptamers, peptides, biodegradable materials, antibody-derived epitope binding domains, cellular ligands, and a combination thereof.
4. The method of claim 1 , wherein the method further comprises determining EN2 and/or SATB2 expression level of said subject.
5. The method of claim 1 , wherein the at least one agent inhibits cancer cell or cancer stem cell growth.
6. The method of claim 1 , wherein the at least one agent is administered in nanoparticles containing an imaging agent with or without a targeting agent.
7. The method of claim 1 , wherein the at least one agent is administered to the subject in combination with one or more chemotherapeutic drugs or radiation for treatment or prevention of cancer.
8. The method of claim 2 , wherein the at least one agent comprises a targeting moiety capable of binding to the surface of a cancer cell, wherein said targeting moiety is selected from the group consisting of aptamers, peptides, biodegradable materials, antibody-derived epitope binding domains, cellular ligands, and a combination thereof.
9. The method of claim 2 , wherein the method further comprises determining EN2 and/or SATB2 expression level of said subject.
10. The method of claim 2 , wherein at least one agent inhibits cancer cell or cancer stem cell growth.
11. The method of claim 2 , wherein the at least one agent is administered in nanoparticles containing an imaging agent with or without a targeting agent.
12. The method of claim 2 , wherein the at least one agent is administered to the subject in combination with one or more chemotherapeutic drugs, immunotherapy, or radiation for treatment or prevention of cancer.
13. The method of claim 1 , wherein the pharmaceutical composition comprises an effective amount of at least one agent that inhibits at least one of SATB2 expression or SATB2 transcriptional activity and at least one agent that inhibits at least one of EN2 expression or EN2 transcriptional activity.